{
    "2019-11-04": [
        [
            {
                "time": "2019-11-04",
                "original_text": "前三季度，这5家药企净利润均超30亿元",
                "features": {
                    "keywords": [
                        "药企",
                        "净利润",
                        "前三季"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "药明康德涨逾4%破顶 绩后曾获里昂升目标价",
                "features": {
                    "keywords": [
                        "药明康德",
                        "涨逾4%",
                        "里昂",
                        "目标价"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "麦格理：下调上海医药(2607.HK)目标价至18.57港元 评级“跑赢大市” 机构下调估值",
                "features": {
                    "keywords": [
                        "麦格理",
                        "上海医药",
                        "下调",
                        "目标价",
                        "跑赢大市"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "麦格理：上海医药给予跑赢大市评级 目标价18.57港元",
                "features": {
                    "keywords": [
                        "麦格理",
                        "上海医药",
                        "跑赢大市",
                        "目标价"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "上海医药涨1.91% 创近1个月新高报19.25元",
                "features": {
                    "keywords": [
                        "上海医药",
                        "涨1.91%",
                        "新高"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "银河国际：上海医药维持增持评级 目标价17.4港元",
                "features": {
                    "keywords": [
                        "银河国际",
                        "上海医药",
                        "增持",
                        "目标价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-04",
                "original_text": "上海医药前三季度盈利33.99亿 同比增长0.8%",
                "features": {
                    "keywords": [
                        "上海医药",
                        "前三季",
                        "盈利",
                        "同比增长"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}